New drug combination shrinks tumors in most pancreatic cancer patients
A new oral medication combined with standard chemotherapy shrank tumors in over 60 percent of advanced pancreatic cancer patients. Researchers presented these promising phase 1/2 clinical trial results at the EORTC-NCI-AACR Symposium in Barcelona on Friday. Specifically, the study tested a daily pill called daraxonrasib alongside two standard intravenous chemotherapy drugs, gemcitabine and…
We haven't written up this one. Daily Times has the full story — the link below goes straight to it.